Cocrystal Pharma
COCP
27 hedge funds and large institutions have $3.95M invested in Cocrystal Pharma in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 1.22% → 1.16% (-0.06%)
18% less funds holding
Funds holding: 33 → 27 (-6)
32% less capital invested
Capital invested by funds: $5.83M → $3.95M (-$1.88M)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$31.2K |
| 2 |
VF
Virtu Financial
New York
|
+$18.7K |
| 3 |
Millennium Management
New York
|
+$4.12K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$2.83K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$236K |
| 2 |
Renaissance Technologies
New York
|
-$38.2K |
| 3 |
BJL
Brighton Jones LLC
Seattle,
Washington
|
-$11K |
| 4 |
WWM
Western Wealth Management
Golden,
Colorado
|
-$10K |
| 5 |
Jane Street
New York
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Jane Street
New York
| – | -$6K | -1,237 | Closed |
|
27
Goldman Sachs
New York
| – | -$5K | -1,062 | Closed |
|
28
Victory Capital Management
San Antonio,
Texas
| – | -$5K | -1,050 | Closed |
|
|
HF
29
HRT Financial
New York
| – | -$5K | -1,042 | Closed |
|
30
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -192 | Closed |
|
31
Osaic Holdings
Scottsdale,
Arizona
| – | -$75 | -16 | -89% |
|
32
Wells Fargo
San Francisco,
California
| – | -$5 | -1 | -1% |
|
COCP Hedge Fund Activity: Q3 2022 in Review
27 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q3 2022, worth a combined $3.95M — down 32% from $5.83M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of COCP and 3 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $31.2K. The largest seller was Sabby Management, cutting an estimated $236K.
- 27 institutional investors held Cocrystal Pharma (COCP) as of Q3 2022, down from 33 in Q2 2022.
- Funds reported $3.95M of Cocrystal Pharma stock for Q3 2022, down 32% quarter-over-quarter.
- 3 funds opened new Cocrystal Pharma positions in Q3 2022 and 9 closed out, a net change of -6 holders.
- The largest Cocrystal Pharma buyer in Q3 2022 was Citadel Advisors, an estimated $31.2K added.
- The largest Cocrystal Pharma seller in Q3 2022 was Sabby Management, an estimated $236K sold.
Based on aggregated 13F filings for Q3 2022.